scholarly journals PHP76 Evidence Requirements for Pricing and Reimbursement Decision Making for Orphan Drugs in Asia

2012 ◽  
Vol 15 (7) ◽  
pp. A621-A622
Author(s):  
S. Tan ◽  
H. Dummett ◽  
S. Kirpekar ◽  
Q. Guan ◽  
V.L. Priest
Author(s):  
Gereltuya Dorj ◽  
Bruce Sunderland ◽  
Tsetsegmaa Sanjjav ◽  
Gantuya Dorj ◽  
Byambatsogt Gendenragchaa

Folia Medica ◽  
2013 ◽  
Vol 55 (3-4) ◽  
pp. 80-86 ◽  
Author(s):  
Georgi G. Iskrov ◽  
Ralitsa D. Raycheva ◽  
Rumen S. Stefanov

ABSTRACT OBJECTIVE: This article’s objective is to critically assess the Bulgarian legislation on health technology assessment (HTA). It analyses how innovative therapies and orphan drugs in particular would respond to the regulators’ decision-making criteria for reimbursement. MATERIALS AND МETHODS: The study features critical analysis of current decision-making criteria for drug reimbursement in Bulgaria, as well as hypothetical scenario planning for orphan medicinal products. RESULTS: The approval for inclusion into the Positive Drug List (PDL) (which is a must for reimbursement) has been reorganised into an assessment scoring system with decisionmaking criteria (presence of therapeutic alternative, clinical effectiveness, safety, pharmacoeconomics and societal value) divided into weighted indicators. An explicit threshold has been set - a medicinal product must score 60 points at least to be included in PDL. Under the currently defined reimbursement decision-making criteria a hypothetical middle- of-the-road scenario planning shows that an orphan drug would score 20 points for therapeutic alternative, 28 for clinical effectiveness and 12 for safety. It would take no points for pharmacoeconomics and societal value. This leaves the orphan drugs with a total score of 60 points, making the final outcome of real-life assessment and decision-making heavily dependent on small fluctuations. CONCLUSIONS: The current reimbursement decision-making framework in Bulgaria seems to be generalised and not sufficiently transparent. It is unable to precisely assess innovative health technologies. The availability of a therapeutic alternative emerges as a key reimbursement decision-making criterion for orphan drugs, as these innovative products nominally provide the first medicinal therapy alternative to rare diseases.


2017 ◽  
Vol 33 (1) ◽  
pp. 111-120 ◽  
Author(s):  
Antoni Gilabert-Perramon ◽  
Josep Torrent-Farnell ◽  
Arancha Catalan ◽  
Alba Prat ◽  
Manel Fontanet ◽  
...  

Objectives:The aim of this study was to adapt and assess the value of a Multi-Criteria Decision Analysis (MCDA) framework (EVIDEM) for the evaluation of Orphan drugs in Catalonia (Catalan Health Service).Methods:The standard evaluation and decision-making procedures of CatSalut were compared with the EVIDEM methodology and contents. The EVIDEM framework was adapted to the Catalan context, focusing on the evaluation of Orphan drugs (PASFTAC program), during a Workshop with sixteen PASFTAC members. The criteria weighting was done using two different techniques (nonhierarchical and hierarchical). Reliability was assessed by re-test.Results:The EVIDEM framework and methodology was found useful and feasible for Orphan drugs evaluation and decision making in Catalonia. All the criteria considered for the development of the CatSalut Technical Reports and decision making were considered in the framework. Nevertheless, the framework could improve the reporting of some of these criteria (i.e., “unmet needs” or “nonmedical costs”). Some Contextual criteria were removed (i.e., “Mandate and scope of healthcare system”, “Environmental impact”) or adapted (“population priorities and access”) for CatSalut purposes. Independently of the weighting technique considered, the most important evaluation criteria identified for orphan drugs were: “disease severity”, “unmet needs” and “comparative effectiveness”, while the “size of the population” had the lowest relevance for decision making. Test–retest analysis showed weight consistency among techniques, supporting reliability overtime.Conclusions:MCDA (EVIDEM framework) could be a useful tool to complement the current evaluation methods of CatSalut, contributing to standardization and pragmatism, providing a method to tackle ethical dilemmas and facilitating discussions related to decision making.


2018 ◽  
Vol 21 ◽  
pp. S166
Author(s):  
C. Ferreira ◽  
B. Vandewalle ◽  
V. Andreozzi ◽  
J. Félix

Sign in / Sign up

Export Citation Format

Share Document